Drug Retailers Industry ESG Material Mapping

HC-DR-230a.1Description of policies and practices to secure customers’ protected health information (PHI) records and other personally identifiable information (PII)

HC-DR-230a.2(1) Number of data breaches, (2) percentage involving (a) personally identifiable information (PII) only and (b) protected health information (PHI), (3) number of customers affected in each category, (a) PII only and (b) PHI

HC-DR-230a.3Total amount of monetary losses as a result of legal proceedings associated with data security and privacy

HC-DR-250a.1Description of efforts to reduce the occurrence of compromised drugs within the supply chain

HC-DR-250a.2Number of drug recalls issued, total units recalled, percentage for private-label products

HC-DR-130a.1(1) Total energy consumed, (2) percentage grid electricity, (3) percentage renewable

HC-DR-260a.1Percentage of controlled substance prescriptions dispensed for which a prescription drug monitoring program (PDMP) database was queried

HC-DR-260a.2Total amount of monetary losses as a result of legal proceedings associated with controlled substances

HC-DR-260b.1First fill adherence rate